We hypothesize that this will lead to the strengthening of the cancer immunity cycle, as depicted in Figure 1C. The exogenous vaccination strategy could benefit from a variety of additional smart design features, including a selection of multiple mutant KRAS epitopes that can be assembled into a single vaccine to cover the heterogeneous tumor landscape that may include more than one KRAS mutant. Here, KRAS is linked to neoplasm.